We are live on ! Find out more
TA

Tamarack Advisers Portfolio holdings

AUM $2.12M
1-Year Est. Return 58.09%
This Fund
S&P 500
This Quarter Est. Return
+8.29%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$329M
AUM Growth
+$77M
Cap. Flow
+$63.4M
Cap. Flow %
19.29%
Top 10 Hldgs %
77.94%
Holding
27
New
5
Increased
10
Reduced
4
Closed
5

Top Buys

Rank Stock Value
1
DGX icon
Quest Diagnostics
DGX
+$18.2M
2
PCRX icon
Pacira BioSciences
PCRX
+$12.9M
3
ZBH icon
Zimmer Biomet
ZBH
+$10.9M
4
BIO icon
Bio-Rad Laboratories Class A
BIO
+$10.5M
5
HAE icon
Haemonetics
HAE
+$9.84M

Top Sells

Rank Stock Value
1
NVRO
NEVRO CORP.
NVRO
+$6.85M
2
LNTH icon
Lantheus
LNTH
+$5.59M
3
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$5.33M
4
ALKS icon
Alkermes
ALKS
+$5.11M
5
SCI icon
Service Corp International
SCI
+$4.82M

Sector Composition

Rank Sector Weight
1 Healthcare 88.73%
2 Industrials 6.8%
3 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDCO
26
PUT
DELISTED
Medicines Co
MDCO
– –
-1,714
Closed -$34K
VSI
27
DELISTED
Vitamin Shoppe Inc.
VSI
– –
-13,158
Closed -$93K
1
2

Similar funds

SCM
SevenOneSeven Capital Management Lancaster, Pennsylvania $2.17M AUM 8.67% 1-Year Est. Return
LBC
Lawrence B. Cohen $2.06M AUM 34.47% 1-Year Est. Return
ICM
ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return
LCMP
Linse Capital Management PR San Juan, Puerto Rico $2.31M AUM
GIP
General Industrial Partners London, United Kingdom $2.57M AUM
STC
Sarah T. Connolly $1.11M AUM 24.13% 1-Year Est. Return
GC
Gilfoyle & Co San Francisco, California $671K AUM
DU
Delphia (USA) Toronto, Ontario, Canada $445K AUM 28.82% 1-Year Est. Return

Tamarack Advisers's Q2 2019 Portfolio in Review

As of Q2 2019, Tamarack Advisers held 27 positions worth $329M, up 31% from $252M the previous quarter. Its ten largest holdings account for 78% of the portfolio.

Tamarack Advisers deployed $63.4M of net new capital in Q2 2019, opening 5 new positions and adding to 10 existing holdings. Its largest new stake was Quest Diagnostics: 188,900 shares worth $19.4M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 77% a quarter earlier, followed by Industrials and Consumer Discretionary.

On the sell side, the largest reduction was NEVRO CORP., an estimated $6.85M trimmed.

  • Tamarack Advisers's largest Q2 2019 buy was Quest Diagnostics: 188,900 shares worth $19.4M.
  • Tamarack Advisers added most to Pacira BioSciences in Q2 2019, an estimated $12.9M increase.
  • Tamarack Advisers's biggest Q2 2019 reduction was NEVRO CORP., cutting an estimated $6.85M.
  • Tamarack Advisers fully exited Alkermes in Q2 2019, selling an estimated $5.11M.
  • Tamarack Advisers's ten largest holdings make up 78% of its $329M portfolio in Q2 2019.
  • Tamarack Advisers opened 5 new positions and closed 5 in Q2 2019.
  • Tamarack Advisers's portfolio value rose 31% quarter-over-quarter to $329M.

Based on Tamarack Advisers's 13F filing for Q2 2019, filed 12 Aug 2019.